

Is Catapres still in shortage in 2026? Get the latest update on Clonidine availability, pricing, and what patients can do to find their medication right now.
If you've been following the Catapres situation, you know it's been a bumpy ride. Brand-name Catapres was discontinued in 2022, and patients have been navigating the aftermath ever since. In this update, we'll cover the current state of Clonidine availability, what it costs, and how to get your medication without hassle.
Let's clear up the confusion: brand-name Catapres is permanently discontinued. It's not coming back. Boehringer Ingelheim stopped making Catapres tablets and Catapres-TTS transdermal patches in 2022 after a recall related to dissolution testing issues. The FDA confirmed in 2023 that this was not due to safety concerns.
However, generic Clonidine — the exact same active ingredient — is not in shortage for most formulations as of early 2026. Here's the current picture:
For more background on why Catapres became hard to find, read Why Is Catapres So Hard to Find?
Even though there's no official shortage of generic Clonidine tablets, some patients still struggle to fill their prescriptions. Here's why:
If your prescription specifically says "Catapres" with a dispense as written (DAW) instruction, your pharmacist cannot substitute the generic. You'll need your doctor to update the prescription to generic Clonidine.
The transdermal patch is the most difficult formulation to find. After Boehringer Ingelheim discontinued Catapres-TTS, demand shifted entirely to generic patch manufacturers. These patches are more complex to produce than tablets, and manufacturers have had difficulty scaling up production consistently.
Clonidine's off-label popularity — especially for ADHD, anxiety, opioid withdrawal, and insomnia — means demand continues to grow. More prescriptions being written means pharmacies can run out faster, especially in high-demand areas.
Some pharmacies limit how much of a particular generic they keep in stock based on historical dispensing patterns. If a pharmacy hasn't filled many Clonidine prescriptions recently, they may not have your strength on hand.
One of the silver linings of the Catapres discontinuation is that generic Clonidine is very affordable. Here's what you can expect to pay:
Most insurance plans cover generic Clonidine immediate-release tablets as a Tier 1 preferred generic, meaning your copay is usually $0 to $10. For all the ways to save, read How to Save Money on Catapres.
Since the brand-name discontinuation, a few developments have expanded patient options:
Here's your action plan:
For detailed tips, read our full guide on how to find Catapres in stock near you.
We can't say this enough: never stop taking Clonidine without your doctor's guidance. Abruptly stopping Clonidine can trigger rebound hypertension — a sudden, dangerous spike in blood pressure. Symptoms can include severe headache, rapid heartbeat, tremors, anxiety, and in serious cases, stroke or heart attack.
If you're running low and can't find your medication, call your doctor immediately. They can help you taper safely or prescribe a bridge supply. Learn more about Catapres side effects and when to call your doctor.
The Catapres brand is gone for good, but the active ingredient — Clonidine — remains available, affordable, and effective. Generic tablets are widely accessible in 2026, though the transdermal patch can be harder to find. Use Medfinder to check stock near you, keep your prescription updated to generic, and talk to your doctor if you're having trouble finding your specific formulation.
For the provider perspective on managing Catapres availability, see Catapres Shortage: What Providers Need to Know.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.